Grant: Doctoral Research Award: Canada Graduate Scholarships
University of Calgary
$105,000.00
STING Activation in Sarcoma: Assessing Translational Therapeutic Strategies
FY 2022-23
Summary
Soft tissue sarcomas (STS) are aggressive cancers that arise from muscle, fat, and blood vessels. Undifferentiated pleomorphic sarcoma (UPS) is one of the most common STS in adults. Treatments for this disease include radiation and extensive surgeries to remove primary tumours. Despite primary tumour removal, the disease commonly spreads to a secondary site, such as the lungs. When this occurs, the disease becomes rapidly fatal as there are no cures. To address this, our lab is investigating a treatment strategy that involves activating the STimulator of INterferon Genes (STING) pathway. The STING pathway is a sensor that exists within all cells in the body and when it is activated, it produces an immune response that can be used to kill cancer cells. Our previous work has shown that an activator of the STING pathway produces impressive anti-tumour responses in our mouse model of UPS. More than 50% of treated mice eliminated their UPS tumours and survived long term with no tumour recurrence. Unfortunately, this drug can only activate the STING pathway in mice and not humans. Therefore, my PhD research will evaluate the potential of STING therapies that can be used in humans. Using our mouse model of UPS, I first will test the curative potential of three newly developed STING activators that can activate both human and mouse STING pathways. Next, I will combine the new STING activators with current primary UPS treatments such as radiation to determine if activating the STING pathway can enhance treatment options currently used in the clinic. Lastly, I will engineer a gene delivery particle that can target tumour cells and force them to express human STING. This will allow me to test whether directly forcing STING expression in tumours can enhance the anti-cancer immune response. If survival benefits are observed from this study, these innovative strategies may revolutionize treatment options for patients battling UPS in hopes of improving their survival outcomes.
Department
Program
Doctoral Research Award: Canada Graduate Scholarships
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
475924
Name
Hildebrand Karys M
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
STING Activation in Sarcoma: Assessing Translational Therapeutic Strategies
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Gene Therapy; Immunotherapy; Soft Tissue Sarcoma; Stimulator Of Interferon Genes Pathway; Undifferentiated Pleomorphic Sarcoma
Abstract
Soft tissue sarcomas (STS) are aggressive cancers that arise from muscle, fat, and blood vessels. Undifferentiated pleomorphic sarcoma (UPS) is one of the most common STS in adults. Treatments for this disease include radiation and extensive surgeries to remove primary tumours. Despite primary tumour removal, the disease commonly spreads to a secondary site, such as the lungs. When this occurs, the disease becomes rapidly fatal as there are no cures. To address this, our lab is investigating a treatment strategy that involves activating the STimulator of INterferon Genes (STING) pathway. The STING pathway is a sensor that exists within all cells in the body and when it is activated, it produces an immune response that can be used to kill cancer cells. Our previous work has shown that an activator of the STING pathway produces impressive anti-tumour responses in our mouse model of UPS. More than 50% of treated mice eliminated their UPS tumours and survived long term with no tumour recurrence. Unfortunately, this drug can only activate the STING pathway in mice and not humans. Therefore, my PhD research will evaluate the potential of STING therapies that can be used in humans. Using our mouse model of UPS, I first will test the curative potential of three newly developed STING activators that can activate both human and mouse STING pathways. Next, I will combine the new STING activators with current primary UPS treatments such as radiation to determine if activating the STING pathway can enhance treatment options currently used in the clinic. Lastly, I will engineer a gene delivery particle that can target tumour cells and force them to express human STING. This will allow me to test whether directly forcing STING expression in tumours can enhance the anti-cancer immune response. If survival benefits are observed from this study, these innovative strategies may revolutionize treatment options for patients battling UPS in hopes of improving their survival outcomes.
Competitiondate
202211
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Hildebrand, Karys M
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~